PMID- 33262624
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 1178-6981 (Print)
IS  - 1178-6981 (Electronic)
IS  - 1178-6981 (Linking)
VI  - 12
DP  - 2020
TI  - Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of 
      Two Systematic Literature Reviews.
PG  - 693-709
LID - 10.2147/CEOR.S274951 [doi]
AB  - PURPOSE: Non-muscle invasive bladder cancer (NMIBC) is a malignancy restricted to 
      the inner lining of the bladder. Intravesical Bacillus Calmette-Guerin (BCG) 
      following transurethral resection of the bladder tumor is the mainstay first-line 
      treatment for high-risk NMIBC patients. Two systematic literature reviews (SLRs) 
      were conducted to further assess the current evidence on BCG use in NMIBC and the 
      humanistic and economic burden of disease. METHODS: Using the Preferred Reporting 
      Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, Embase((R)) and 
      MEDLINE((R)) were searched using the Ovid platform to identify interventional or 
      real-world evidence studies on the health-related quality of life (HRQoL) and 
      economic burden in NMIBC. Limited evidence was found from initial economic SLR 
      searches in NMIBC, so additional targeted searches for bladder cancer were 
      conducted to expand findings. RESULTS: Fifty-nine publications were included in 
      the HRQoL SLR, of which 23 reported HRQoL and symptoms in NMIBC. At diagnosis, 
      HRQoL was comparable with population norms but worsened considerably 2 years 
      following diagnosis. Maintenance therapy with intravesical BCG was associated 
      with reduced HRQoL, and treatment-related adverse events (AEs) resembled typical 
      NMIBC symptoms. Twenty-two studies reported decreasing BCG compliance over time. 
      Common AEs with BCG were frequent urination, lower urinary tract symptoms, pain, 
      and hematuria. Forty-two publications were included in the economic SLR, of which 
      nine assessed healthcare costs and resource use in NMIBC or bladder cancer. 
      High-risk disease and high-intensity treatment were associated with increased 
      healthcare costs. CONCLUSION: NMIBC has a considerable symptomatic, HRQoL, and 
      economic burden. Symptoms persisted and HRQoL worsened despite intravesical BCG 
      treatment. NMIBC is a costly disease, with higher healthcare costs associated 
      with increased risk of disease progression and recurrence. There is a high unmet 
      need for safe and effective treatments that reduce the risk of disease 
      progression and recurrence, provide symptomatic relief, and improve HRQoL for 
      patients.
CI  - (c) 2020 Lee et al.
FAU - Lee, Lauren J
AU  - Lee LJ
AD  - Patient Health and Impact, Pfizer Inc, New York, NY, USA.
FAU - Kwon, Christina S
AU  - Kwon CS
AUID- ORCID: 0000-0002-9536-6085
AD  - Evidence Generation, Purple Squirrel Economics, New York, NY, USA.
FAU - Forsythe, Anna
AU  - Forsythe A
AD  - Evidence Generation, Purple Squirrel Economics, New York, NY, USA.
FAU - Mamolo, Carla M
AU  - Mamolo CM
AUID- ORCID: 0000-0001-5321-561X
AD  - Patient Health and Impact, Pfizer Inc, Groton, CT, USA.
FAU - Masters, Elizabeth T
AU  - Masters ET
AD  - Patient Health and Impact, Pfizer Inc, New York, NY, USA.
FAU - Jacobs, Ira A
AU  - Jacobs IA
AD  - Worldwide Research and Development, Pfizer Inc, New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201123
PL  - New Zealand
TA  - Clinicoecon Outcomes Res
JT  - ClinicoEconomics and outcomes research : CEOR
JID - 101560564
PMC - PMC7695604
OTO - NOTNLM
OT  - NMIBC
OT  - costs
OT  - health-related quality of life
OT  - symptoms
COIS- Ira A Jacobs, Lauren J Lee, Carla M Mamolo, and Elizabeth T Masters are employees 
      of Pfizer Inc. and own Pfizer stock. Christina S Kwon and Anna Forsythe are 
      employees of Purple Squirrel Economics who were paid consultants to Pfizer in 
      connection with the development of this manuscript. The authors report no other 
      conflicts of interest in this work.
EDAT- 2020/12/03 06:00
MHDA- 2020/12/03 06:01
PMCR- 2020/11/23
CRDT- 2020/12/02 05:32
PHST- 2020/07/31 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/12/02 05:32 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/03 06:01 [medline]
PHST- 2020/11/23 00:00 [pmc-release]
AID - 274951 [pii]
AID - 10.2147/CEOR.S274951 [doi]
PST - epublish
SO  - Clinicoecon Outcomes Res. 2020 Nov 23;12:693-709. doi: 10.2147/CEOR.S274951. 
      eCollection 2020.